Search Result

Isoforms Recommended:	p38α

Results for "

p38α

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (1) AP-1 (1) Apoptosis (16) Autophagy (33) Bacterial (1) Bcl-2 Family (1) Bcr-Abl (1) c-Kit (1) c-Myc (1) Cadherin (2) Casein Kinase (13) Caspase (2) CDK (1) Cholinesterase (ChE) (3) Collagen (1) COX (1) Dengue Virus (1) Discoidin Domain Receptor (1) Drug Isomer (1) EGFR (1) Epigenetic Reader Domain (1) ERK (4) Interleukin Related (11) Isotope-Labeled Compounds (1) JAK (1) JNK (9) MAP3K (1) MAPKAPK2 (MK2) (3) MDM-2/p53 (1) MMP (1) NF-κB (3) Organoid (4) p38 MAPK (128) PAI-1 (1) Parasite (2) PGE synthase (1) Phosphatase (1) PROTACs (5) Pyk2 (1) Raf (2) Reactive Oxygen Species (ROS) (2) Reference Standards (17) Src (7) Syk (2) TGF-beta/Smad (3) TGF-β Receptor (9) Tie (2) TNF Receptor (12) VEGFR (6) Wee1 (1) Wnt (4) β-catenin (2)
By Research Areas:	Cancer (59) Cardiovascular Disease (8) Endocrinology (1) Infection (3) Inflammation/Immunology (90) Metabolic Disease (12) Neurological Disease (19)
Click Chemistry:	Alkynes (2)

144

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10320

Doramapimod 50+ Cited Publications BIRB 796	p38 MAPK Raf Autophagy	Inflammation/Immunology Cancer
Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC₅₀ for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (K_d=0.1 nM). Doramapimod also inhibits B-Raf with an IC₅₀ of 83 nM .

HY-10328

Neflamapimod 5+ Cited Publications VX-745	p38 MAPK Autophagy	Inflammation/Immunology
Neflamapimod (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of *p38α* inhibitor with an IC₅₀ for p38α of 10 nM and for p38β of 220 nM. Neflamapimod (VX-745) possesses anti-inflammatory activity.

HY-10403

PH-797804 5+ Cited Publications	p38 MAPK Autophagy	Inflammation/Immunology Cancer
PH-797804 is a ATP-competitive, selective *p38α/p38β* inhibitor (IC₅₀=26 nM and K_i=5.8 nM for p38α; K_i=40 nM for p38β) and does not inhibit JNK2.

HY-10402

Losmapimod 10+ Cited Publications GSK-AHAB; GW856553X; SB856553	p38 MAPK Autophagy	Inflammation/Immunology Cancer
Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pK_is of 8.1 and 7.6 for p38α and p38β, respectively .

HY-12299

WH-4-023 5 Publications Verification Dual LCK/SRC inhibitor	Src	Cancer
WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC₅₀ of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.

HY-16782

Pexmetinib 2 Publications Verification ARRY-614	Tie p38 MAPK Autophagy	Cancer
Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC₅₀s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.

HY-10401

VX-702 4 Publications Verification	p38 MAPK Autophagy	Inflammation/Immunology
VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β .

HY-18874

p38-α MAPK-IN-1 2 Publications Verification	p38 MAPK Autophagy	Others
p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC₅₀ of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay .

HY-13241A

Ralimetinib 10+ Cited Publications LY2228820	p38 MAPK Autophagy	Cancer
Ralimetinib is an ATP-competitive *p38α* and *p38β* MAPK inhibitor with an IC₅₀ of 5.3 nmol/L against human *p38α* and an IC₅₀ of 3.2 nmol/L against human *p38β*. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma .

HY-11068

SB 239063 30+ Cited Publications	p38 MAPK Autophagy	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC₅₀ of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD. SB 239063 can penetrate the blood brain barrier (BBB) .

HY-139553

Zunsemetinib ATI-450; CDD-450	MAPKAPK2 (MK2)	Inflammation/Immunology
Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases .

HY-120111

MW-150 MW01-18-150SRM	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K_i of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

HY-107597

Halicin 2 Publications Verification SU3327	JNK	Metabolic Disease Inflammation/Immunology
Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC₅₀ of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC₅₀ of 239 nM. Halicin shows less active against p38α and Akt kinase .

HY-10406

Talmapimod 3 Publications Verification SCIO-469	p38 MAPK TNF Receptor Interleukin Related VEGFR Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Talmapimod (SCIO-469) is an orally active and selective inhibitor of p38α MAPK with an IC₅₀ of 9 nM. Talmapimod inhibits the secretion of inflammatory factors (such as TNFα, IL-1β, IL-6, and VEGF) by suppressing the p38α MAPK pathway, and it also inhibits angiogenesis and osteoclast activation. Talmapimod inhibits the growth of multiple myeloma cells and induces apoptosis. Talmapimod can be used to study various hematological malignancies (such as multiple myeloma, myelodysplastic syndrome) .

HY-108642

AMG-548	p38 MAPK Casein Kinase	Inflammation/Immunology
AMG-548, an orally active and selective *p38α* inhibitor (K_i=0.5 nM), shows slightly selective over *p38β* (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG 548 is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC₅₀=3 nM) . AMG-548 inhibits Wnt signaling by directly inhibiting Casein kinase 1 isoforms δ and ε .

HY-123961

SJF-8240	PROTACs p38 MAPK	Cancer
SJF-8240 is a selective *p38α* PROTAC degrader. SJF-8240 promotes ubiquitination and selective degradation of p38α. SJF-8240 can be used in breast cancer-related research .

HY-114404

SJFα	PROTACs p38 MAPK	Cancer
SJFα is a selective p38α PROTAC degrader with a DC₅₀ of 7.16 nM and D_max of 97.4%. SJFα is far less effective at degrading p38δ (DC₅₀ = 299 nM). SJFαcan be used for the research of cancer, such as breast cancer . (Structure Note: Pink: p38α ligand (HY-45124); Blue: VHL ligand (HY-125845))

HY-14975

R1487 Hydrochloride 1 Publications Verification	p38 MAPK Autophagy	Cancer
R1487 Hydrochloride is a highly potent and selective *p38α* inhibitor, with K_d values of 0.2 nM and 29 nM for p38α and p38β, respectively .

HY-11087

SD 0006 SD-06	p38 MAPK Autophagy	Inflammation/Immunology
SD 0006 (SD-06) is an orally active, selective, ATP-competitive and potent diaryl pyrazole inhibitor of p38α MAP kinase, with an IC₅₀ of 110 nM for p38α .

HY-16715

Acumapimod 1 Publications Verification BCT197	p38 MAPK Autophagy	Inflammation/Immunology
Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC₅₀ of less than 1 μM for p38α.

HY-10405

Pamapimod 1 Publications Verification Ro4402257; R1503	p38 MAPK Autophagy	Inflammation/Immunology
Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC₅₀s of 14 nM and 480 nM and K_is of 1.3 nM and 120 nM for *p38α* and *p38β*, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .

HY-112182

UM-164 1 Publications Verification DAS-DFGO-II	Src p38 MAPK Autophagy	Cancer
UM-164 (DAS-DFGO-II) is a highly potent inhibitor of c-Src with a K_d of 2.7 nM. UM-164 also potently inhibits *p38α* and *p38β*.

HY-108642B

AMG-548 dihydrochloride	p38 MAPK Casein Kinase	Inflammation/Immunology
AMG-548 dihydrochloride, an orally active and selective *p38α* inhibitor (K_i=0.5 nM), shows slightly selective over *p38β* (K_i=36 nM) and >1000 fold selective against p38γ and p38δ. AMG-548 dihydrochloride is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC₅₀=3 nM) . AMG-548 dihydrochloride inhibits Wnt signaling by directly inhibiting Casein kinase 1 isoforms δ and ε .

HY-18303

AMG-47a 3 Publications Verification	Src VEGFR p38 MAPK JAK	Inflammation/Immunology
AMG-47a is an orally active, ATP-competitive Lck inhibitor (IC₅₀=0.2 nM). AMG-47a inhibits VEGF2, *p38α, p38α, Jak3, MLR, and IL-2* with IC₅₀ of 1 nM, 3 nM, 72 nM, 30 nM, and 21 nM, respectively. AMG-47a reduces T cell activation and the production of cytokines such as TGF-β, exerting anti-inflammatory and anti-fibrotic activities. AMG-47a can be used in the research of autoimmune diseases, pulmonary fibrosis, and KRAS mutation-associated cancers[1][2][3].

HY-131335

p38α inhibitor 2	p38 MAPK	Inflammation/Immunology
p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC₅₀ of 9.6. p38α inhibitor 2 inhibits the hERG ion channel (IC₅₀=27 μM) and shows a promising selectivity profile when tested in a panel of 51 other protein kinases (<30% inhibition at 10 μM concentration) and a panel of 141 other biological targets .

HY-112401

p38 MAP Kinase Inhibitor IV	p38 MAPK	Inflammation/Immunology
p38 MAP Kinase Inhibitor IV is a highly specific ATP-competitive p38α MAPK inhibitor with IC₅₀s of 0.13 and 0.55 μM for p38α and p38β MAPK, respectively .

HY-153932

NR-7h	PROTACs p38 MAPK	Cancer
NR-7h is a potent and selective *p38α* and *p38β* degrader with DC₅₀ values of 24 nM and 27.2 nM for p38α in T47D, MB-MDA-231 cells, respectively .

HY-W015445

SD-169	p38 MAPK	Metabolic Disease
SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC₅₀ of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC₅₀ of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation .

HY-114423

p38α inhibitor 1	p38 MAPK Autophagy	Inflammation/Immunology
p38α inhibitor 1 is a *p38α* inhibitor extracted from patent WO 2008076265 A1.

HY-159799

p38α inhibitor 5	p38 MAPK	Cancer
p38α inhibitor 5 (compound 1) is a PROTAC-type target protein ligand targeting p38 and can be used to synthesize NR-11c (HY-159798) .

HY-135674

SR-318 1 Publications Verification	p38 MAPK TNF Receptor	Inflammation/Immunology Cancer
SR-318, a chemical probe, is a potent and highly selective p38 MAPK inhibitor with IC₅₀s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively. SR-318 potently inhibits the TNF-α release in whole blood with an IC₅₀ of 283 nM. SR-318 has anti-cancer and anti-inflammatory activity .

HY-172807

p38α-IN-9	p38 MAPK MAPKAPK2 (MK2) CDK Wee1	Cancer
p38α-IN-9 (Compound 2015) is a *p38α* inhibitor and blocks p38α’s enzymatic activity with an IC₅₀ lower than 20 nM. p38α-IN-9 inhibits MK2 ^T334 phosphorylation. p38α-IN-9 activates Cdc25b and Cdc25c and simultaneously inactivates Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy and DNA damage. p38α-IN-9 Inhibits colorectal cancer (CRC) metastasis .

HY-120823

PF-05381941	MAP3K p38 MAPK	Inflammation/Immunology
PF-05381941 is a potent dual inhibitor of *TAK1/p38α, with IC₅₀*s of 156 and186 nM, respectively .

HY-N8251

Cyclocurcumin	p38 MAPK	Cardiovascular Disease Inflammation/Immunology
Cyclocurcumin is a potent *p38α* inhibitor. Cyclocurcumin shows antirheumatic, antivasoconstrictive and antioxidant activities .

HY-145564

Emprumapimod PF-07265803	p38 MAPK	Cardiovascular Disease Inflammation/Immunology
Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC₅₀=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain .

HY-15505

RWJ-67657 JNJ 3026582	p38 MAPK	Cardiovascular Disease Inflammation/Immunology Cancer
RWJ-67657 (JNJ 3026582) is an orally active and selective *p38α* and p38β MAPK inhibitor with IC₅₀s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity .

HY-14305A

BMS-582949 hydrochloride 2 Publications Verification	p38 MAPK Autophagy	Inflammation/Immunology
BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC₅₀ of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease .

HY-108645

AL 8697	p38 MAPK Autophagy	Inflammation/Immunology
AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC₅₀ of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC₅₀=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity .

HY-114221

Org 48762-0 UR13870	p38 MAPK	Inflammation/Immunology
Org 48762-0 (UR13870) is a potent, orally active and selective *p38* inhibitor with an EC₅₀ of 0.1 μM for p38α kinase. Org 48762-0 shows a high degree of kinase selectivity for p38α and p38β over other kinases. Org 48762-0 reduces Lipopolysaccharides (HY-D1056) (LPS)-induced TNFα release. Org 48762-0 can be used for the study of rheumatoid arthritis (RA) and Werner syndrome .

HY-161462

*ERK2/p38α* MAPK-IN-1**	ERK p38 MAPK	Cancer
ERK2/p38α MAPK-IN-1 (Compound 1, In silico Hit-2) is a potent and selective ERK2 and p38α MAPK inhibitor, with an IC₅₀ of 82 μM for ERK2. ERK2/p38α MAPK-IN-1 binds to the allosteric site of ERK2 and p38α MAPK in distinct manners. ERK2/p38α MAPK-IN-1 can be used for the research of type 2 diabetes .

HY-14412

p38α inhibitor 4	p38 MAPK	Cancer
p38α inhibitor 4 (compound 10) is a selective and allosteric *p38α* inhibitor with an IC₅₀ value of 1.2 μM. p38α inhibitor 4 exhibits no activity against p38β, p38γ, and p38δ .

HY-170879

JD123	p38 MAPK JNK	Cancer
JD123 inhibits JNK1 activity and the expression of cJun (1-135). JD123 is a ATP-competitive p38-γ MAPK inhibitor, but not effect to ERK1, ERK2, or p38-α, p38-β or p38-δ. .

HY-147518

p38-α MAPK-IN-5	p38 MAPK	Inflammation/Immunology
p38-α MAPK-IN-5 (compound 4e) is a potent *p38α* inhibitor with IC₅₀s of 0.1 nM, 0.2 nM, 944 nM, 4100 nM for p38α, p38 β, p38γ, p38δ, respectively. p38-α MAPK-IN-5 has anti-inflammatory effect. p38-α MAPK-IN-5 has the potential for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-153002

p38α inhibitor 3	p38 MAPK	Inflammation/Immunology
p38α inhibitor 3 (Comp G7) is a *p38α* inhibitor that blocks the effectiveness of myoblast differentiation .

HY-116836

p38α inhibitor 7	p38 MAPK	Inflammation/Immunology
p38α inhibitor 7 (compound 1) is an effective *p38α* inhibitor with oral efficacy and generally favorable pharmacokinetic properties .

HY-159938

p38α inhibitor 6	p38 MAPK Apoptosis Bcl-2 Family MDM-2/p53 Caspase	Cancer
p38α inhibitor 6 (compound 19) is a *p38α* inhibitor with the IC₅₀ of 0.68 μM. p38α inhibitor 6 induces cell apoptosis and arrests cell cycle at G0 and G2/M phase. p38α inhibitor 6 decreases the TNF-α concentration as well as increased the expression of tumor suppressor gene p53, Bax/BCL-2 ratio and caspase 3/7 .

HY-175655

*BChE/p38-α* MAPK-IN-1**	p38 MAPK Cholinesterase (ChE) Interleukin Related	Neurological Disease Inflammation/Immunology
BChE/p38-α MAPK-IN-1 is a selective dual inhibitor of hBChE (IC₅₀ = 772 nM) and p38α MAPK (IC₅₀ = 191 nM). BChE/p38-α MAPK-IN-1 reduces the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) in cells. BChE/p38-α MAPK-IN-1 improves Scopolamine (HY-N0296)-induced cognitive impairment, as well as alleviates LPS (HY-D1056)-induced spatial learning impairment and exerts anti-neuroinflammatory effects in mice. BChE/p38-α MAPK-IN-1 can be used for the study of Alzheimer’s disease (AD) by targeting both cholinergic deficit and neuroinflammation .

HY-171300

p38α inhibitor 8	p38 MAPK Casein Kinase	Inflammation/Immunology
p38α inhibitor 8 (Compound 1) exhibits inhibitory activity against p38α MAPK and CK1δ with IC₅₀ of 0.21 µM and 0.202 µM ^[1]>.

HY-171297

p38-α MAPK-IN-10	p38 MAPK	Inflammation/Immunology
p38-α MAPK-IN-10 (Compound 6) is the inhibitor for *p38α* with an IC₅₀ of 4 nM .

HY-146032

p38-α MAPK-IN-4	p38 MAPK	Neurological Disease Inflammation/Immunology
p38-α MAPK-IN-4 (Compound 69) is a selective p38α MAPK inhibitor with an IC₅₀ of 1.5 µM. p38-α MAPK-IN-4 rapidly and strongly prevents the development of mechanical allodynia (MA) in vivo .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0841

Bruceine A 3 Publications Verification Dihydrobrusatol; NSC310616	Infection Triterpenes Simaroubaceae Classification of Application Fields Terpenoids Plants Disease Research Fields Brucea javanica (L.) Merr. Source Classification	Parasite NF-κB p38 MAPK Phosphatase Apoptosis
Bruceine A (Dihydrobrusatol) is a natural quassinoid. Bruceine A is an inhibitor of parasites, NF-κB, and PFKFB4 (K_d: 44 nM). Bruceine A is an activator of P38α MAPK. Bruceine A has antiparasitic activity. Bruceine A has antitumor activity and inhibits cancer cell migration. Bruceine A blocks the cell cycle and induces apoptosis. Bruceine A can be used in parasites, pancreatic cancer, and breast cancer research .

HY-N2375

L-Quebrachitol	Natural Products other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Source Classification	Wnt β-catenin p38 MAPK
L-Quebrachitol is a methoxy analog of inositol that can be isolated from plants. L-Quebrachitol has free-radical scavenging, gastroprotection, anti-platelet aggregation and anti-diabetic activity. L-Quebrachitol promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway .

HY-N6857

Armepavine	Structural Classification Classification of Application Fields Plants Nymphaeaceae Alkaloids Monophenols other families Phenols Nelumbo nucifera Gaertn. Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Source Classification	AP-1 NF-κB p38 MAPK ERK JNK
Armepavine, found in Nelumbo nucifera, is an orally active NF-κB inhibitor. Armepavine attenuates expression of p-p65, α-SMA, p-JNK1/2, p-ERK1/2, p-p38α stimulated by TNF-α and LPS. Armepavine suppresses NF-κB nuclear translocation, IκBα phosphorylation, and collagen deposition. Armepavine can be used for the research of hepatic fibrosis and leukemia .

HY-N8251

Cyclocurcumin	Phenols Polyphenols Plants Curcuma longa Source Classification Zingiberaceae	p38 MAPK
Cyclocurcumin is a potent *p38α* inhibitor. Cyclocurcumin shows antirheumatic, antivasoconstrictive and antioxidant activities .

HY-N0346

4-Methoxycinnamic acid ethyl ester Ethyl p-methoxycinnamate	Structural Classification Kaempferia galanga L. Iridoids Terpenoids Plants Source Classification Zingiberaceae	COX NF-κB TNF Receptor Interleukin Related Apoptosis VEGFR Bacterial Dengue Virus Caspase
4-Methoxycinnamic acid ethyl ester (Ethyl p-methoxycinnamate) is an orally active natural compound found. 4-Methoxycinnamic acid ethyl ester exerts anti-inflammatory effects by inhibiting cyclooxygenase (COX-1 (IC₅₀ = 1.12 μM) and COX-2 (IC₅₀ = 0.83 μM)), NF-κB (IC₅₀ = 88.7 μM) and cytokine production (TNF-α (IC₅₀ = 96.84 μg/mL) and IL-1β (IC₅₀ = 166.4 μg/mL)). 4-Methoxycinnamic acid ethyl ester inhibits tumor cell proliferation, migration and cancer metabolism and induces apoptosis.4-Methoxycinnamic acid ethyl ester inhibits VEGF expression, thereby inhibiting angiogenesis. 4-Methoxycinnamic acid ethyl ester has a significant inhibitory effect on dengue virus and Mycobacterium tuberculosis. 4-Methoxycinnamic acid ethyl ester has analgesic effects in rats .

HY-N2375R

L-Quebrachitol (Standard)	Structural Classification Natural Products other families Plants Source Classification	Reference Standards Wnt β-catenin p38 MAPK
L-Quebrachitol is a methoxy analog of inositol that can be isolated from plants. L-Quebrachitol has free-radical scavenging, gastroprotection, anti-platelet aggregation and anti-diabetic activity. L-Quebrachitol promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway .

Cat. No.	Product Name	Chemical Structure

HY-10405S

Pamapimod-d4

Pamapimod-d₄ (Ro4402257-d₄) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC₅₀s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .

Host:	Mouse (1) Rabbit (2)
Reactivity:	Human (3) Rat (2) Mouse (3)
Application:	IHC-P (1) ICC/IF (3) IP (1) WB (3) FC (1) ELISA (3)
Isotype:	IgG (2) IgG1 (1)
Conjugation:	Non-conjugated (3)
Clonality:	Polyclonal (1) Monoclonal (2)
Modification:	Phosphorylated (1) Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80776A

	Phospho-p38 alpha/MAPK14 (Thr180+Tyr182) Antibody 1 Publications Verification p38 (phospho T180 + Y182); p-p38 (phospho T180 + Y182); p38 (phospho T180/Y182); CSAID Binding Protein 1; CSAID binding protein; CSAID-binding protein; Csaids binding protein; CSBP 1; CSBP 2; CSBP; CSBP1; CSBP2; CSPB 1; CSPB1; Cytokine suppressive anti inflammatory drug binding protein; Cytokine suppressive anti-inflammatory drug-binding protein; EXIP; MAP kinase 14; MAP kinase MXI2; MAP kinase p38 alpha; MAPK 14; MAPK14; MAX interacting protein 2; MAX-interacting protein 2; Mitogen Activated Protein Kinase 14; Mitogen activated protein kinase p38 alpha; Mitogen-activated protein kinase 14; Mitogen-activated protein kinase p38 alpha; MK14_HUMAN; Mxi 2; Mxi2; p38 ALPHA; p38; p38 MAP kinase; p38 MAPK; p38 mitogen activated protein kinase; p38ALPHA; p38alpha Exip; PRKM14; PRKM15; RK; SAPK 2A; SAPK2A; Stress Activated Protein Kinase 2A.	WB, IHC-P, FC, ICC/IF, ELISA	Human, Mouse
	Phospho-p38 alpha/MAPK14 (Thr180+Tyr182) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-p38 alpha/MAPK14 (Thr180+Tyr182).

HY-P85712

	p38 alpha/MAPK14 Antibody (YA5404) Mitogen-activated protein kinase 14; MAP kinase 14; MAPK 14; Cytokine suppressive anti-inflammatory drug-binding protein; CSAID-binding protein; CSBP; MAP kinase MXI2; MAX-interacting protein 2; Mitogen-activated protein kinase p38 alpha; MAP kinase p38 alpha; Stress-activated protein kinase 2a; SAPK2a;	WB, ICC/IF, ELISA	Human, Mouse, Rat
	p38 alpha/MAPK14 Antibody (YA5404) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to p38 alpha/MAPK14.

HY-P86460

	p38 alpha/MAPK14 Antibody (YA6152) Mitogen-activated protein kinase 14; MAP kinase 14; MAPK 14; Cytokine suppressive anti-inflammatory drug-binding protein; CSAID-binding protein; CSBP; MAP kinase MXI2; MAX-interacting protein 2; Mitogen-activated protein kinase p38 alpha; MAP kinase p38 alpha; Stress-activated protein kinase 2a; SAPK2a;	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	p38 alpha/MAPK14 Antibody (YA6152) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p38 alpha/MAPK14.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-159799

p38α inhibitor 5		Alkynes
p38α inhibitor 5 (compound 1) is a PROTAC-type target protein ligand targeting p38 and can be used to synthesize NR-11c (HY-159798) .

HY-125387

TOP1210		Alkynes
TOP1210 is a narrow-spectrum tyrosine kinase inhibitor with potent inhibitory activity against P38α, Src, and Syk kinases. TOP1210 effectively reduced proinflammatory cytokines released by peripheral blood monocytes, primary macrophages, HT29 cells, inflammatory cells in ulcerative colitis (UC) biopsies, and myofibroblasts isolated from inflamed colonic UC mucosa. TOP1210 showed significant anti-inflammatory effects in cell experiments and UC biopsies, superior to some selective kinase inhibitors. The multi-kinase inhibition of TOP1210 provides the possibility of obtaining a wider range of therapeutic effects, especially in the regulation of autoimmune responses .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks